Oppenheimer raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $65 from $63 and keeps an Outperform rating on the shares.

Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...

Reports Q3 revenue $55.3M, consensus $41.93M. “2024 has been a significant year for Rigel, marked by the acquisition of GAVRETO, our ...

Third Quarter 2024 Results Key Financial Results Revenue: US$33.3m (up 48% ...

The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

The United States Agency for International Development has announced a $2.3m commitment to procure 4.8 million doses of ...

The U.S. Agency for International Development (USAID) has committed $2.3 million to procure 4.8 million doses of life-saving ...

Bruce, Professional Relations Associate, 3M Pharmaceuticals, personal communication, March 2007). Of interest to us were the four subjects (15%) with reactions to fragrance mix. The positive ...

Investigations revealed that a French pharmaceutical company fell victim to a business e-mail impersonation scam by the ...

Merck-Sharp and Dohme), screening for HPV (Digene Corp.), and HPV therapy (3M Pharmaceuticals). Eduardo Franco has served as an occasional paid consultant to pharmaceutical and biotechnology ...

Community Health Network is suing insurer Humana Inc., claiming the Louisville company owes it $7.4 million in drugs for its ...